Paul Kohlhaas

Moving research from concept to market is like conducting a symphony - there are numerous players and stakeholders, each bringing their unique expertise to work in harmony and advance a project.

By “tokenizing everything,” from preclinical data to final-stage IP, and layering in decentralized governance, BIO brings the industry’s biggest friction points into the open. Suddenly, drug development feels more like science fiction than a glacial marathon.

What if we could funnel memecoin liquidity into funding science? Crypto would be regarded in a completely different light by the public.